Drug Profile
Autologous ovalbumin-specific type 1 T lymphocyte cell therapy - TxCell
Alternative Names: Autologous ovalbumin-specific regulatory T lymphocytes - TxCell; Crohn's disease autologous T cell therapy - TxCell; Ova-Treg - TxCell; Ovalbumin-specific Type 1 Treg cells - TxCell; OvaSave®Latest Information Update: 09 Oct 2018
Price :
$50
*
At a glance
- Originator TxCell
- Class Anti-inflammatories; Cell therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action Immunosuppressants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 01 Oct 2018 TxCell has been acquired by Sangamo Therapeutics
- 06 Feb 2018 Discontinued - Phase-II for Crohn's disease (Treatment-resistant) in France, United Kingdom, Italy, Austria, Germany and Belgium (IV) (Not listed on TxCell pipeline, February 2018)
- 24 Nov 2016 TxCell terminates the phase II CATS29 trial in Crohn's disease (Treatment-resistant) in Austria, Belgium, France, Germany, Italy and United Kingdom (NCT02327221)